Achieve is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe for more than 20 years. It is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase 3 clinical trials in Europe and New Zealand. Achieve initiated a Phase 2b Optimization Trial (ORCA-1) evaluating cytisinicline in the United States and data is expected in mid-2019. The Phase 3 cytisinicline development program is expected to begin by the end of 2019. Achieveâs focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. Smoking is currently the leading cause of preventable death and is responsible for nearly six million people losing their lives annually worldwide. Source
No articles found.
We are an established, commercial-stage diagnostics company committed to reducing ...
We are an established, commercial-stage diagnos...
LivaNova is a global medical technology company built on decades of experience and...
LivaNova is a global medical technology company...
An emerging leader in the specialty pharmaceuticals industry, ANI Pharmaceuticals ...
An emerging leader in the specialty pharmaceuti...
YiLo Life uses organic methods and the finest ingredients to create cannabis produ...
YiLo Life uses organic methods and the finest i...
Join the National Investor Network and get the latest information with your interests in mind.